10 December 2008: 4. Quarter 2008 and Preliminary results: February 26 2009 [...]

10 December 2008:

4. Quarter 2008 and Preliminary results: February 26 2009

Annual General Meeting: April 29 2009

1. Quarter 2009: May 13 2009

2. Quarter 2009: August 26 2009

3. Quarter 2009: October 29 2009

Contact:
CFO Tone Kvåle, Phone: +47 915 19576

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.